Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents

Trial Profile

Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2015

At a glance

  • Drugs Budesonide (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Therapeutic Use
  • Acronyms PEER
  • Sponsors Shire
  • Most Recent Events

    • 02 Oct 2015 Association has been changed from Meritage Pharma to Shire, end points has been changed as reported by ClinicalTrials.gov record.
    • 11 May 2011 New trial record
    • 10 May 2011 Results presented at Digestive Disease Week 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top